Key facts
- This page summarizes June Sherie Almenoff's Form 4 filing for BRAINSTORM CELL THERAPEUTICS INC. (BCLI).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 17 Dec 2021, 16:02.
June Sherie Almenoff - 15 Dec 2021 Form 4 Insider Report for BRAINSTORM CELL THERAPEUTICS INC. (BCLI)
- Reporting relationship
- Director
- Issuer ticker
- BCLI
- Reported as of
- 15 Dec 2021
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 17 Dec 2021, 16:02:35 UTC
- Prior SEC filing
- 10 Dec 2021
- Next SEC filing
- 04 Jan 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ June Sherie Almenoff
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
June Sherie Almenoff filed Form 4 for BRAINSTORM CELL THERAPEUTICS INC. (BCLI) on 17 Dec 2021.
Change
- Previous filing in this sequence was filed on 10 Dec 2021.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
BCLI
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +2,000
- Change %
- +50%
- Price
- $0.000000
- Shares after
- 6,000
- Date
- 15 Dec 2021
- Ownership
- Direct
- Footnotes
- F1
BCLI
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 7,175
- Date
- 15 Dec 2021
- Ownership
- By Meadowlark Management LLC
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Shares acquired are shares of restricted stock awarded in connection with the Company's 2021 Annual Meeting of Stockholders pursuant to the Company's Second Amended and Restated Director Compensation Plan. The shares of restricted stock vest in 12 consecutive, equal monthly installments commencing on January 15, 2022 until fully vested on the first anniversary of December 15, 2021.
Footnote F2
The reporting person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for the purposes of Section 16 or for any other purpose.